Michel D'Incan
Michel D'Incan is an expert in Dermatology at Centre Hospitalier Universitaire de Clermont-Ferrand (France). Michel D'Incan has authored 318 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 2 of them ongoing. SLR score: 749 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Hematology - Immunology - Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2025
Number : 318
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. PMID 41651641 — mycosis fungoides, safety, progression-free survival, sezary syndrome, disease progression, maintenance, drug-related side effects and adverse reactions, therapeutics | Lancet Haematol | 2026 | 0 |
| [Cutaneous T-cell lymphomas]. PMID 39510908 — skin, cells, mycosis fungoides, lymphoma, neoplasms, lymphoma, t-cell, cutaneous, diagnosis, therapeutics, t-lymphocytes, lymphoma, t-cell | Bull Cancer | 2024 | 0 |
| Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model. PMID 40898695 — skin, cells, growth, melanins, melanoma, skin diseases, immunotherapy, cell line, therapeutics, pigmentation | Exp Dermatol | 2025 | 0 |
| Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors. PMID 39908046 — antibodies, adrenal cortex hormones, cohort studies, skin diseases, rituximab, therapeutics, pemphigus | JAMA Dermatol | 2025 | 5 |
| Increased risk of cutaneous squamous cell carcinomas in patients with Sézary syndrome: A nationwide multicenter retrospective study. PMID 40127782 — cells, epidemiology, sezary syndrome, carcinoma, squamous cell, retrospective studies, carcinogenesis, immunosuppression therapy, dermatology | J Am Acad Dermatol | 2025 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence NCT06692556 — radiotherapy, skin, cells, carcinoma, squamous cell, brachytherapy, neoplasms, radiotherapy, adjuvant, beds, therapeutics, nervous system, carcinoma, cutaneous squamous cell carcinoma | Phase 3 | Recruiting | 2025 |
| Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus NCT05898308 — injections, skin, antibodies, adrenal cortex hormones, skin diseases, desmogleins, biomarkers, maintenance, rituximab, precision medicine, acantholysis, therapeutics, pemphigus | Phase 4 | Recruiting | 2024 |
LeadR Networks
Main global connection map